Comprehensive Assessment of the Biosimilarity of Protein Biotherapeutics Based on Ion Signal Statistics in LC/MS Peptide Mapping Data
Stephane Houel
Monday, July 7, 2014
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
Methods
Comparing Innovator vs. Biosimilar 1 & 2
Intensity of Features and Distribution
Frequency of Fold Change
Results - Unique Features of Innovator vs. Biosimilar 1 & 2
Intensity Distribution of Unique Features
MS/MS of Unique Features of Biosimilar 2
Differences of Innovator vs. Biosimilar 1 & 2
Ratio Between Innovator vs. Biosimilar 1 & 2
Expression Profile
Conclusion
No transcript for this webinar
More Information
Brochure
Download Poster